千葉大学医学部附属病院は、千葉県千葉市中央区亥鼻にある千葉大学の附属病院。千葉大学亥鼻キャンパスの東側に面している。

During the past decade, Chiba University Hospital conducted 80 clinical trials. In the 10-year time frame, 80 clinical trials started and 32 clinical trials were completed, i.e. on average, 40% percent of trials that started reached the finish line to date. In the past 5 years, 45 clinical trials started and 20 clinical trials were completed. i.e. 44.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Chiba University Hospital" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Pfizer" with 8 trials sponsored, "Janssen Research & Development, LLC" with 7 trials sponsored, "Takeda" with 7 trials sponsored and "Chiba University" with 7 trials sponsored. Other sponsors include 63 different institutions and companies that sponsored additional 50 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Chiba University Hospital" #1 collaborator was "Eisai Co., Ltd." with 2 trials as a collaborator, "Japan Agency for Medical Research and Development" with 2 trials as a collaborator, "Japan Lung Cancer Society" with 2 trials as a collaborator, "Merck Sharp & Dohme LLC" with 2 trials as a collaborator and "Astellas Pharma Inc" with 1 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Chiba University Hospital" are "Advanced Hepatocellular Carcinoma" (3 trials), "Amyotrophic Lateral Sclerosis" (3 trials), "Atrial Fibrillation" (3 trials), "Carcinoma, Hepatocellular" (3 trials) and "Crohn's Disease" (3 trials). Many other conditions were trialed in "Chiba University Hospital" in a lesser frequency.

Most popular intervention types in "Chiba University Hospital" are "Drug" (82 trials), "Device" (8 trials), "Other" (7 trials), "Biological" (5 trials) and "Dietary Supplement" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Atezolizumab" (5 trials), "Bevacizumab" (4 trials), "Nipocalimab" (4 trials) and "Sorafenib" (4 trials). Other intervention names were less common.

The vast majority of trials in "Chiba University Hospital" are 101 trials for "All" genders, 3 trials for "Male" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Chiba University Hospital". undefined are not yet recruiting, 20 are recruiting, 21 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 49 completed trials in Chiba University Hospital, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Chiba University Hospital, 4 "Phase 1" clinical trials were conducted, 26 "Phase 2" clinical trials and 57 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 5 trials, and there were also 6 trials that are defined as “Not Applicable".